Article
Resistance Mutations A30K and Y93N Associated with Treatment Failure with Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection Non-Responder Patients: Case Reports.
Viruses - 31 Oct 2019
Costa Vanessa D, Pellegrini Patricia, Rotman Vivian, Pittella Ana Maria, Nunes Estevão P, Lago Barbara V, Lampe Elisabeth, Mello Francisco C A
Abstract excerpt
In Brazil, hepatitis C treatment has been evolving significantly with the licensing of direct-acting antivirals (DAAs). However, viral determinants (amino acid substitutions in hepatitis C virus (HCV) genome and infective genotype) associated with host factors (hepatic condition and prior HCV therapy) might limit the achievement of sustained virologic response (SVR). Here, we described two case reports in which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.